HOME >> BIOLOGY >> NEWS
Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients

Results in Treatment of Hospital Patients with Complicated Skin Infections Reported in Clinical Therapeutics

Oklahoma City, OK An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI). Tigecycline, a candidate antibiotic drug, produced these promising results in a study led by Russell G. Postier, M.D., OU Physicians Chairman of Surgery and John A. Schilling Professor of Surgery at the University of Oklahoma College of Medicine.

"Tigecycline displayed promising efficacy against a wide spectrum bacteria commonly related to complicated skin infections, with an acceptable safety profile. These data warrant further investigation in blinded comparator clinical trials, said Postier, John A. Schilling Professor and chairman of surgery, OU Physicians and the study's principle investigator. Results of the multicenter, phase 2 will be published in the May 2004, issue of Clinical Therapeutics.

In the study, 85 percent of patients who received 50-milligram (mg) doses of tigecycline were cured at the end of their seven- to 14-day treatment, and 74 percent were cured at the test-of-cure visit (the study's primary outcome measure), about 21 days after their initial dose of tigecycline. Similarly, 78 percent of patients on the 25-mg doses were cured at the end of treatment, and 67 percent at the test-of-cure visit. The decline in rates directly resulted from patients receiving either additional antibiotics or surgery between the end of their treatments and their test-of-cure visits.

The 50 mg group also had a higher overall bacterial eradication rate at the end of therapy, 74 percent, than the 62 percent rate of the 25 mg group. At the test-of-cure visit, the rates were 70 and 56, respectively. Additionally, the trial used laboratory tests to document tigecycline activity against
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
23-May-2004


Page: 1 2 3

Related biology news :

1. Tigecycline - antibiotic evaluated in surveillance trial
2. AAAS US Presidential Candidates Forum
3. US Presidential Candidates Forum
4. Candidate genes found which may play a role in cancer progressing from non-invasive to invasive
5. UCSD And NIH Researchers Isolate Candidates For Genetic Basis Of Human Taste
6. New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)
7. Candidate Regulator Of The Temporal Component Of Neurotransmitter Release Identified
8. Duke Researchers Discover Candidate Susceptibility Gene For Autoimmune Disease
9. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
10. Smart antibiotics may result from UCLA research
11. K-State researcher working to improve alternatives to equine antibiotics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/30/2019)... , ... September 30, 2019 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... Experiment and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem ... for studying the development and diseases of the human heart, there is an increasing ... progeny heart muscle cells to be clearly and easily recorded. A study released today ...
(Date:9/30/2019)... Calif. (PRWEB) , ... September ... ... a leading think tank, research, and public interest organization focused on molecular ... Distinguished Student Prize. , The Award recognizes the College graduate or undergraduate ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 01, 2019 , ... Today ... itself, announced the midway point of its randomized research trial for individuals with ... to measure the efficacy of a non-invasive technology which compares tones delivered to ...
(Date:10/3/2019)... ... October 02, 2019 , ... Murrieta Genomics , the launch ... venture capital companies in Silicon Valley at a special Life Science showcase event ... be held at the JJ Lake Business Center located at 340 E. Middlefield Road ...
(Date:10/3/2019)... ... ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials New England ... Ph.D., discussed important design factors that currently limit the success of early stage stem ... clinical trials, in his talk Dr. Sherley focused on the highly problematic ...
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared as one ... with MRSA becoming one of the most serious concerns. Hong Kong cannot be spared ... community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – the year ...
Breaking Biology Technology:
Cached News: